A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma

Trial Profile

A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2015

At a glance

  • Drugs Capecitabine (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
  • Indications Intestinal cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 22 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 09 Nov 2012 New source identified and integrated (Mayo clinic).
    • 18 Jun 2012 Planned End Date changed from 1 Sep 2008 to 1 Dec 2012 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top